Company Selvita S.A.

Equities

SLV

PLSLVCR00029

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Selvita S.A.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Warsaw S.E. Other stock markets 12:49:55 02/05/2024 pm IST			5-day change	1st Jan Change
68.9 ^PLN	-1.01%		-1.15%	+17.78%

28/03	Selvita S.A. agreed to acquire PozLab sp. z o.o.	CI
27/03	Selvita S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.

Number of employees: 886

PLN in Million	2022	Weight	2023	Weight	Delta
Services Executed in Poland 62.7 %	220	52.9 %	221	62.7 %	+0.35%
Services Executed in Croatia 38.2 %	148	35.5 %	134	38.2 %	-9.13%
Elimination of Intersegment Revenue -0.9 %	-4	-1.0 %	-3	-0.9 %	-18.46%

PLN in Million	2022	Weight	2023	Weight	Delta
European Union 38.2 %	159	39.1 %	133	38.2 %	-16.73%
United States 24.8 %	118	29.0 %	86	24.8 %	-27.25%
United Kingdom 17.2 %	65	15.9 %	60	17.2 %	-8.20%
Switzerland 10.1 %	30	7.4 %	35	10.1 %	+16.97%
Other Countries 5.6 %	14	3.4 %	19	5.6 %	+39.76%
Poland 4.1 %	15	3.6 %	14	4.1 %	-2.02%

Managers	Title	Age	Since
Boguslaw Sieczkowski CEO	Chief Executive Officer	-	01/07/01
Dariusz Kurdas DFI	Director of Finance/CFO	-	01/19/01
Miroslawa Zydron COO	Chief Operating Officer	-	02/09/02
Dean Bornilla SAM	Sales & Marketing	-	19/21/19
Adrijana Vinter PRN	Corporate Officer/Principal	-	01/22/01
Dawid Radziszewski LAW	General Counsel	-	01/15/01
Milosz Gruca PRN	Corporate Officer/Principal	-	01/07/01

Members of the board	Title	Age	Since
Jacek Osowski BRD	Director/Board Member	47	19/19/19
Pawel Przewiezlikowski BRD	Director/Board Member	-	19/19/19
Tadeusz Wesolowski BRD	Director/Board Member	72	-
Rafal Chwast BRD	Director/Board Member	-	-
Piotr Romanowski CHM	Chairman	-	01/11/01
Wojciech Chabasiewicz BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,355,474	14,442,242 ( 78.68 %)	0	78.68 %

Name	Equities	%	Valuation
Pawel Przewiezlikowski 16.63 %	3,052,663	16.63 %	51 M zł
Nationale-Nederlanden PTE SA 10.36 %	1,901,000	10.36 %	32 M zł
Boguslaw Sieczkowski 5.134 %	942,417	5.134 %	16 M zł
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA 4.734 %	868,990	4.734 %	15 M zł
FORUM TFI SA 4.618 %	847,738	4.618 %	14 M zł
Vienna PTE SA Vienna Insurance Group 3.485 %	639,761	3.485 %	11 M zł
Allianz Polska TFI SA 2.148 %	394,264	2.148 %	7 M zł
Generali PTE SA 1.772 %	325,181	1.772 %	5 M zł
PKO TFI SA 1.584 %	290,740	1.584 %	5 M zł
Investors TFI SA 1.480 %	271,752	1.480 %	5 M zł

Selvita SA

79 Podole Street

30-394, Kraków

+48 122 97 47 00

http://www.selvita.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

69.6 PLN

Average target price

71.28 PLN

Spread / Average Target

+2.41%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
SELVITA S.A.	+17.78%	315M
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+46.40%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research